AcceGen

  Prostate cancer (PCa)  is the most common malignant tumor and estimated to be the second leading cause of cancer death in men in the United States. It is reported that the overall prostate cancer incidence annually declined 7% from 2011 to 2015.[1] However, PCa is still the first threat that endangers men’s health despite the continuous improvement of living standards and modern medical techniques. [2].     Figure 1. Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths by Sex, United States, 2019. Ranking is based on modeled projections and may differ from the most recent observed data[1].   Even though substantial researches on prostate cancer have been conducted, abundant in vivo and in vitro experiments are still required when exploring the mechanism of advanced cancer[3]. Therefore, it is crucial to grasp the biological characteristics of common prostate cancer cells.  LNCaP ,  PC3 , and  22Rv1  were commonly used cell lines in the research of prostate cancer. T

  Human single cells are the key materials for research and production of cell therapy products. Yet, the purchase of fresh cells may be restricted, so there is an urgent need for suitable alternative cells that are viable and powerful[1].   Leukopak  is the product of this demand.   What are Leukopaks and Leukapheresis? Leukopaks  ( LPs )  are leukapheresis samples obtained from healthy peripheral blood [2].  Leukapheresis  is a specially modified apheresis technique designed to remove leukocyte and return the remaining cells (i.e, granulocytes, platelets, red blood cells) to the donor. The operation of plasma leukopenia can be performed in vitro with a small amount of liquid (200-300mL of plasma). It is not necessary to perform plasma exchange and blood product perfusion before surgery. Therefore, this is an ideal method for obtaining blood components from participants without exposing them or their blood to other people’s substances[3].   The percentage of cells can vary from donor